To date, epidemiologic research on 1,3-butadiene has consisted of cohort mortality studies of workers in the styrene-butadiene rubber (SBR) and butadiene monomer industries. These studies have been extremely useful both in defining the focus on human health effects to the lymphopoietic cancers and in providing a perspective on which to evaluate the available animal models for human risk assessment. The next step for epidemiologic research will involve a lymphopoietic cancer case control approach to enable a more precise assessment of whether there is a relationship between 1,3-butadiene exposure and lymphopoietic cancer. In addition, periodic mortality updates of the 1,3-butadiene-exposed worker cohorts will be important to monitor trends in lymphopoietic cancer rates and to ensure that other cancers with long latency do not begin to show elevated rates. This paper describes an industry-sponsored program of case-control and cohort mortality update studies along with the critical elements in research design and analysis for each study. Epidemiological studies will play an important role in testing hypotheses developed from toxicological studies about potential biological mechanisms of 1,3-butadiene carcinogenesis in humans.
Introduction
In our attempt to understand the potential human health risks of exposure to 1,3-butadiene, we are quite fortunate to have available a considerable amount of toxicological and epidemiological data. In this latter regard, the update ofthe three available epidemiological studies (1-3) provides additional information on the mortality experience of workers with occupational 1,3-butadiene exposure. The purpose of this paper is to discuss future areas for epidemiological research. Some of the study areas have already been incorporated into the International Institute of Synthetic Rubber Producer's (IISRP) epidemiology program, funded jointly by the IISRP and the butadiene monomer producers. Other study areas are longer term and await developments in related scientific fields.
Perhaps the best way to set the stage for discussing future epidemiologic research related to 1,3-butadiene is to consider the present status of epidemiologic research, identify existing data gaps and important methodologic issues that need to be resolved, and plan studies to address these issues. In addition, this paper discusses anticipated related toxicological developments and points out where epidemiologic studies can contribute to refining or testing specific hypotheses.
Cohort Studies of Worker Mortality
The previous three papers are examples of historical *Monsanto Company, A2SL, 800 North Lindbergh Boulevard, St. Louis, MO 63167. prospective cohort (or follow-up) mortality studies (1) (2) (3) . Cohort mortality studies begin by defining a worker population (the cohort) at a point in time (1943 for these studies) and following workers prospectively to assess each individual's vital status at the end of the study period. Death rates for workers are then compared with general population rates. Additionally, for large cohorts, there may be comparisons of rates between exposed and unexposed workers. Since a cause of death is determined for almost all decedents in the cohort, these studies allow an evaluation of death rates for workers for many causes of death. However, since cohort studies typically involve thousands of workers, assembling detailed exposure data or making exposure estimates for each worker is often impractical, limiting the potential to study exposure-disease relationships. Accordingly, these cohort studies are particularly useful to assess whether rates for many causes of death are elevated among worker populations and to generate hypotheses for further, more detailed, studies of specific occupational subgroups.
Summary of Findings
A comprehensive review of 1,3-butadiene epidemiology is beyond the scope ofthis paper and is the topic of the succeeding two papers (4, 5 
Impact on Risk Assessment
While the cohort studies of 1,3-butadiene-exposed workers have provided an important perspective on worker mortality rates, these studies are often not useful for risk assessment modeling because exposure estimates are not available for individual workers. However, despite this limitation, the human data can be used to evaluate projected worker mortality based on risk estimates (unit risks) derived from the chronic rat (10) and mouse (11) bioassays. This analysis requires two simplifying assumptions: a) that workers on the average were exposed to a specific exposure level (in this example, 1, 5, and 10 ppm were used since these levels are consistent with the available monitoring data as shown in Fig. 1) ; and b) that any excess mortality would be from lymphopoietic cancer (following directly from the previous summary of findings).
For example, based on the largest published SBR workers study (8) to date, Figure 2 compares the observed human lymphopoietic cancer mortality (the white bar) and the mortality predicted based on the unit risk estimates from the rat (10) (grey bar) and mouse (11 (black bar) models, assuming that the average workerexposure levels were 1, 5, and 10 ppm. The horizontal line on the graph is the level where the animal models significantly overpredict the observed human mortality. The numbers in parentheses on top of the bars are the probabilities of seeing as few or fewer deaths among SBR workers if the excess cancer risk was as great as that predicted by the animal models. From this figure, it is clear that the mouse model significantly overpredicts human mortality at average exposure levels of 1 ppm and greater levels, which current monitoring data tell us still exist in SBR facilities (12) . Projections based on the rat model are less severe, but they still seem to overpredict human mortality at levels of 5 ppm or greater. Clearly then, to the extent that the two assumptions above are reasonable, the human data offer a perspective on the worker mortality projections, based on the existing animal models for 1,3-butadiene. In the same way, future developments from toxicological studies should be evaluated, where possible, against the available epidemiological data.
Importance of Continued Follow-up
In light of the approximate 40-year study period for each of these cohorts, the question arises: Is there anything to be gained by continuing the follow-up period for these workers? Clearly, the answer to this question is that much remains to be learned from cohort mortality studies of 1,3-butadiene-exposed workers. Specifically, until more is known about the applicability of the animal models, the continued monitoring of the workers' mortality experience will be a critical component of any future research program. In this regard, maintaining a current data base of human mortality will be important to assess temporal trends in cancer mortality, especially for cancers that may occur with long latent periods, and to aid in evaluating new leads from continued toxicological research. Accordingly, future research priorities within the IISRP include a continuation of the SBR workers mortality study soon after completing detailed studies of the relationship between lymphopoietic cancer and 1,3-butadiene exposure. Obviously, continued follow-up of the National Institute for Occupational Safety and Health (NIOSH) (1) and Texaco (3) cohorts would provide useful parallel efforts.
Four modifications should be considered to improve the data from future cohort mortality studies. First, the usefulness of the human mortality data would be greatly improved by a realignment of the lymphopoietic cancer categories used in the mortality analyses. This realignment should reflect the current thinking on the characteristics of the individual lymphopoietic cancer cell types. The three studies reported today have employed lymphopoietic cancer groups that mix potentially re- A second suggestion would be to use local mortality rates for comparisons of worker mortality. At present, interpretation of SMRs for 1,3-butadiene-exposed workers is clouded by variability that is introduced by using U.S. mortality rates as a basis for evaluating worker mortality at plants scattered throughout the U.S. and Canada. Mortality rates for U.S. states and counties and for Canadian provinces are available from several sources and should be incorporated in future mortality studies. To date, only the previously published Texaco study used local rates for their mortality analysis (7). The importance of using local rates was vividly illustrated in that study, as comparisons based on both U.S. and local rates showed that local general population lymphosarcoma rates were 30% higher than U.S. rates.
A third suggestion would be to present lymphopoietic cancer SMRs for various latency/duration of employment subgroups. The purpose of this suggestion is to have the authors specify which, if any, subgroups are showing elevated lymphopoietic cancer rates. At that point, data across studies could be evaluated as suggested by Doll (13) to see if increased risk varies appropriately with intensity and duration of exposure and time after exposure begins and ends; and is observed repeatedly in different circumstances. At present, it is impossible to apply these criteria to the 1,3-butadiene literature.
A final methodologic suggestion would be to evaluate lifetime work histories for a sample of short-term employees in each of these cohort studies. This evaluation would review work experience before and after employment in 1,3-butadiene-related occupations. Clearly, the findings of lymphopoietic cancer excesses among shortterm workers suggests that possible longer employment in other industries must be considered in interpreting the results in 1,3-butadiene-related industries.
Lymphopoietic Cancer Case Control Studies
Prior to initiating another mortality update of the IISRP SBR workers cohort study (8) , the IISRP research program is focusing on detailed studies of a potential relationship between 1,3-butadiene exposure and lymphopoietic cancer(s). The most common research design for this purpose is the nested case-control study. The term "nested" refers to the fact that cases and controls are selected from within the cohort for which mortality data are available. In contrast to cohort studies, case-control studies usually concentrate on one disease or a related group of diseases and compare the odds of previous exposure for those with the disease (the cases) versus those without the disease (the controls). Since nested case-control studies focus on a small subgroup of an occupational cohort (namely those with a specific disease and a sample of nondiseased workers), considerably more attention can be given to the data available for each study subject. This allows detailed evaluation in two critical areas: validation of lymphopoietic cancer diagnoses and estimation of historical 1,3-butadiene exposures.
Validation of lymphopoietic cancer diagnoses is extremely important for case-control studies in light of the unreliability of lymphopoietic cancer diagnoses on death certificates. Perhaps the best study on this issue to date was conducted by the National Center for Health Statistics. In this study, Percy et al. (14) looked at the death certificate diagnosis for more than 48,000 cancer deaths from the Third National Cancer Survey and compared this information to the primary cancer site reported on the hospital diagnosis. This analysis showed considerable underdiagnosis and misclassification of the individual lymphopoietic cancer types. For example, Table 2 shows that only 79.9% of lymphocytic leukemia deaths would have been detected from death certificate diagnoses. Further, of those specified as lymphocytic leukemias on death certificates, only 86.3% could be confirmed from hospital records. A more recent study by Gittlesohn, for the period 1968 to 1978, showed a onethird decline in lymphosarcoma and reticulum cell sarcoma as death certificate diagnoses and a corresponding doubling of the number of deaths attributed to unspecified malignancy of lymphoid tissue (15) . Clearly then, case-control research should incorporate confirmation of the diagnoses and cell type, when possible, for each lymphopoietic cancer. Otherwise, the valid assessment of the relationship between 1,3-butadiene and the individual lymphopoietic cancer cell types will be obscured by the mixing of unrelated lymphopoietic and Table 3 .
Phase I is using diagnostic information from workers' death certificates to select cases of lymphopoietic cancer based on either the underlying or a contributing cause of death. Exposure to 1,3-butadiene and styrene was estimated for both cases and controls in two steps. First, a dictionary of job titles was developed across all eight plants included in the cohort study. Then an industry workgroup rated the exposure potential of each job title on high/medium/low/no and 0 to 10 scales. These ratings reflected the opinions ofthe industry workgroup and did not employ available monitoring data. From these exposure estimates, a cumulative exposure potential score was developed for each worker as the sum of the exposure score times the time spent in each job. The analysis is currently ongoing to determine whether 
